


ChemComm

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



ChemComm

COMMUNICATION

Application of Good's buffers to pH imaging using hyperpolarized ^{13}C MRI

Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

Robert R Flavell^a, Cornelius von Morze^a, Joseph E. Blecha^a, David Korenchan^a, Mark Van Criekeing^a, Renuka Sriram^a, Jeremy Gordon^a, Hsin-Yu Chen^a, Sukumar Subramaniam^a, Robert Bok^a, Zhen J. Wang^a, Daniel Vigneron^a, Peder Larson^a, John Kurhanewicz^a, and David M Wilson^{a,*}

N-(2-Acetamido)-2-aminoethanesulfonic acid (ACES), one of Good's buffers, was applied to pH imaging using hyperpolarized ^{13}C magnetic resonance spectroscopy. Rapid NMR- and MRI-based pH measurements were obtained by exploiting the sensitive pH-dependence of its ^{13}C chemical shift within the physiologic range.

Metabolic reprogramming in cancer results in increased secretion of acid into the extracellular space. This results in an interstitial microenvironment that is slightly acidic, ranging from pH 6.5 – 7.0 for many cancer subtypes, in contrast with normal healthy tissue which characteristically has pH 7.2 – 7.4. This property has been characterized by techniques including microelectrode measurements, magnetic resonance, and fluorescence.^{1–3} Moreover, acidification of the extracellular microenvironment accompanies local invasion and metastasis in a variety of tumors.^{4–6} Treatment of solid tumors with sodium bicarbonate increases tumor pH and reduces metastasis.⁷ Interstitial acidity is thought to induce resistance to chemotherapeutic agents, and many small molecule agents targeting acid transporters are currently under development.^{8, 9} Thus, acidic extracellular pH represents both a therapeutic target as well as a potential biomarker for the presence of aggressive cancer with higher risk of metastases.

Several magnetic resonance techniques, have been developed for the purpose of imaging acidic interstitial pH, including methods based on magnetic resonance spectroscopy (MRS) and chemical exchange saturation transfer (CEST).^{6, 10–14} A central requirement for these techniques is accuracy, since the pH change between healthy and diseased tissues is small. In the MRS strategy, a probe that has a known chemical shift response to pH changes is administered systemically. The chemical shift is then measured using MRS, and by comparison to a standard curve, the pH can be determined. This approach has been studied using several different nuclei, including

^{31}P ,^{15–17} ^1H ,^{18–20} and ^{19}F .^{21, 22} While these techniques have provided important insights in animal model systems, they have various potential limitations, including long scan time, requirement for high dose of probe administration, and in some cases, poor spatial resolution.

Hyperpolarized ^{13}C MRS is an emerging technology which relies upon dramatic NMR signal enhancement provided *via* dynamic nuclear polarization (DNP).²³ This method has been applied to numerous chemical substrates,²⁴ and successfully translated to the clinic for use in men with prostate cancer.²⁵ An elegant pH imaging strategy using hyperpolarized ^{13}C MRS to study the equilibrium between bicarbonate and CO_2 has been reported.^{26, 27} However, this technique has practical limitations, including 1) low signal to noise ratio of the CO_2 resonance under typical physiologic conditions (since $\text{pK}_{\text{a, bicarbonate}} = 6.17$), potentially propagating significant errors to pH estimates derived from this ratiometric approach, 2) the short effective T_1 relaxation time of bicarbonate *in vivo*,²⁶ 3) the relatively low solubility of bicarbonate in glassing agents resulting in difficulty producing sufficient polarized material, and 4) the possibility for inhibition of carbonic anhydrase,²⁸ which is required for rapid equilibration between bicarbonate and CO_2 .

Since relative chemical shifts can in general be measured very accurately using MRS, spectroscopic, or frequency specific imaging techniques, we reasoned that a hyperpolarized ^{13}C approach employing a pair of probes with and without pH-dependent chemical shift could address some of the limitations of this prior approach. Specifically, this approach combines the robustness and high accuracy of chemical shift based MRS methods with the high signal to noise ratio inherent to hyperpolarized ^{13}C imaging.

Initially, a small library of compounds was tested with thermal equilibrium NMR, comparing ^{13}C chemical shifts of long- T_1 nuclei at pH 6.5 and 7.4 (Supplemental fig. 1). These compounds were selected based on the following key criteria: 1) pK_{a} near the physiologic range (between 6.0 and 8.0), 2) presence of a long T_1 nucleus, and 3) feasibility of isotopic synthesis. Agents likely to be toxic were excluded. The classes of compounds examined included

^a Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94158, United States

* To whom correspondence should be addressed: David.m.wilson@ucsf.edu
Electronic Supplementary Information (ESI) available: Materials and methods, supplementary figures, and characterization data for all new compounds.




Fig. 1. Structures of Good's buffers. Long T_1 nuclei are indicated in red. The difference in chemical shift between pH 6.5 and 7.4 is shown for long T_1 nuclei. A positive δ ppm indicates a downfield ^{13}C chemical shift. pKa are based on prior literature values.

biological buffers, dicarboxylic acids, and imidazole/histidine derivatives.

In his landmark 1966 paper, Dr. N. Good described criteria for an optimal biological pH buffer, and synthesized a small series of compounds which have since become the standard buffers used in biochemistry.²⁹ The criteria included pKa between 6 and 8, water solubility, impermeability to biological membranes, minimum influence of temperature, concentration, or ionic strength on dissociation of the buffer, lack of binding to other biological cations, resistance to degradation, and easy synthetic preparation. We rationalized that these properties would also yield optimal pH imaging probes. Moreover, these compounds have been used widely in the 50 years since their initial description, reducing the likelihood of novel interactions which could block pH dependent chemical shift change.

Four of Good's buffers with long T_1 nuclei, and Tris, another commonly used biological buffer, are depicted in Figure 1. Of these, the compounds with the largest chemical shifts were ADA and ACES (Figure 1, Supplemental figures 2-6). In initial studies, we found that the pH dependent chemical shift change of ADA was blocked by the presence of calcium, consistent with its known chelation properties (Supplemental table 1).²⁹

Thus, we selected ACES as the most promising overall compound for imaging, due to the large pH dependant chemical shift, synthetic




Fig. 2. Synthesis of ^{13}C , ^{15}N , ^{13}C ACES.

accessibility, predicted lack of toxicity, and known lack of chelation of abundant biological cations. ^{13}C , ^{15}N ACES was synthesized in 4 steps starting from $1\text{-}^{13}\text{C}$ glycine in 54% overall yield, based on the

previous synthesis of the natural abundance material combined with a previously described technique for the preparation of isotopically enriched amino acids (Figure 2).^{29, 30} Secondary labelling with ^{15}N was incorporated in order to eliminate low field quadrupolar T_1 relaxation effects associated with ^{14}N as well as to increase the T_2 relaxation time for imaging purposes.³¹ This came at the expense of splitting of the ^{13}C peak by the spin-1/2 ^{15}N nucleus, which could potentially limit the accuracy of chemical shift measurement and signal to noise.

Since endogenous ^{13}C nuclei are not abundant enough to allow for *in vivo* imaging, we added a second compound, ^{13}C urea, as a chemical shift standard. Urea was selected since its ^{13}C chemical shift is close to that of the ACES carbonyl, and hyperpolarized ^{13}C , ^{15}N urea is a well characterized imaging agent.³² A titration curve was developed comparing the chemical shifts of ACES and urea (Figure 3). Values for δ_{min} , δ_{max} and pKa were obtained by iteratively fitting the data, yielding the following equation linking chemical shift difference to pH, in a manner similar to previously described:¹⁵

$$pH = 6.58 - \log_{10} \left(\frac{\delta + 13.92}{-5.51 - \delta} \right)$$

The pKa obtained using this technique, 6.58 (at 37 degrees), is in agreement with the previously published value of 6.56.²⁹




Figure 3. Titration curve depicting the difference in chemical shift between urea and ACES as a function of pH.

A method for hyperpolarization of ^{13}C , ^{15}N ACES was developed and optimized with respect to microwave frequency and concentration of Gd-DOTA (Supplemental table 2). The optimized prep was obtained by dissolution of ^{13}C , ^{15}N ACES in 0.95 equivalents NaOH (using a 10M solution), and addition of Gd-DOTA to 0.5 mM, with 20 mM OX63 trityl radical.³³ Using this method, $12.5 \pm 2.7\%$ ($n = 3$) average liquid state polarization, back calculated to the time of dissolution was obtained. The T_1 was 18 s at 11.7T and 25 s at 3T. The polarization time constant was 2490 ± 396 (s.d., $n = 10$). A copolarization method³⁴ was developed to simultaneously polarize ^{13}C , ^{15}N ACES and ^{13}C , ^{15}N urea. By copolarizing ^{13}C , ^{15}N ACES and ^{13}C , ^{15}N urea, we were able to accurately determine the pH of solutions in a 500 MHz NMR (Figure 4). There was a slight but significant change in the measured pH by variation of temperature (Supplemental figure 8) and by variation of concentration of the probe (Supplemental figure 9). Furthermore, there was a slight change in the pH measured at the earliest time points in comparison to those measured at the latest time points (Supplemental figure 10). This change may be related to initial

variation in temperature, and limitations of the kinetics of the acid base equilibria (although these are known to be very rapid reactions in most cases³⁵). Overall, these data suggest that the $^{13}\text{C},^{15}\text{N}$ ACES and $^{13}\text{C},^{15}\text{N}$ urea copolarization method could be used to determine the pH in an imaging experiment.




Figure 4. Measurement of pH with $^{13}\text{C},^{15}\text{N}$ ACES. The calculated pH values of 7.16 and 6.86 correlated with the values of 7.22 and 6.91 measured on a pH meter following the experiment. The carboxylate of $^{13}\text{C},^{15}\text{N}$ ACES is a doublet owing to coupling with the adjacent ^{15}N .

In order to assess the properties of this system under imaging conditions, a five compartment phantom was imaged on a clinical 3T scanner (Figure 5). Again, the dramatic chemical shift change of ACES in response to pH allowed for rapid determination of pH. There was a slight difference in pH calculated from the chemical shift and that measured on a pH meter following the experiment. These differences, averaging 0.18 pH units, may be due to a combination of factors, including temperature (supplemental figure 8), concentration (3 mM in the phantom, supplemental figure 9), the presence of phosphate buffer in the solution (supplemental table 3), or the early time point used for imaging (supplemental table 10), and are similar to previously described phantom experiments for imaging pH using hyperpolarized ^{13}C bicarbonate.^{36, 37} At present, we propose that the accuracy of measured vs. calculated pH is within 0.1 – 0.2 pH units, although a much larger series of experiments would be necessary to truly estimate the accuracy (Supplemental figure 11). *In vivo* pH imaging is a key future goal for this probe. Based on the phantom experiments, we predict that injection of 0.5 mg ACES should be sufficient to generate appropriate signal to noise in a mouse, for a total dose of 25 mg/kg. Since the administered probe could potentially buffer pH, one important goal is the optimization of signal to noise ratio, as well as accuracy of the method. In order to achieve this goal, synthesis of other isotopically labelled variants is currently underway in our laboratory, including ^{14}N (to minimize signal loss due to the splitting by ^{15}N), and ^2H labelled probes (to improve the T_1 of the molecule).

Overall, these data demonstrate that hyperpolarized $^{13}\text{C},^{15}\text{N}$ ACES can be used to determine pH using ^{13}C magnetic resonance spectroscopy. Initially, a series of compounds was screened for a large chemical shift change over the physiologically relevant pH range. Of these compounds, Good's buffers were the most promising, owing to properties considered in their initial design, coupled with the vast experience of their use. We selected $^{13}\text{C},^{15}\text{N}$ ACES owing to the large chemical shift change over the physiologic range and lack of chelation properties. This compound was applied to pH measurement in an NMR spectrometer and in a chemical shift imaging experiment on a clinical 3T MRI scanner. $^{13}\text{C},^{15}\text{N}$ ACES is a promising tool for imaging pH using hyperpolarized ^{13}C MRS, and we anticipate application of this probe to imaging in animal models of malignancy.




Figure 5. Five compartment phantom for imaging pH using $^{13}\text{C},^{15}\text{N}$ ACES and $^{13}\text{C},^{15}\text{N}$ urea A) Phantom design incorporated 5 compartments with varying pH. B) 2D chemical shift imaging through the phantom. C) Representative voxel from position 2. D) Summary of calculated and measured pH values.

Acknowledgements

R.R.F. acknowledges support from NIH 5T32EB0011631-10, a University of California, San Francisco Department of Radiology Seed Grant, a Radiology Society of North America research fellow grant, and an SNMMI-ERF William and Mitzi Blahd, MD Pilot Grant. D.M.W. acknowledges support from NIH R01CA166766. C.V.M. acknowledges support from NIH K01DK099451. This project was also supported by NIH center grant P41EB013598.

Notes and references

1. T. Volk, E. Jahde, H. P. Fortmeyer, K. H. Glusenkaamp and M. F. Rajewsky, *Br J Cancer*, 1993, **68**, 492-500.

2. G. Helmlinger, F. Yuan, M. Dellian and R. K. Jain, *Nature medicine*, 1997, **3**, 177-182.
3. R. A. Gatenby and R. J. Gillies, *Nat Rev Cancer*, 2004, **4**, 891-899.
4. K. R. Keshari, R. Sriram, B. L. Koelsch, M. Van Criekinge, D. M. Wilson, J. Kurhanewicz and Z. J. Wang, *Cancer Res*, 2013, **73**, 529-538.
5. V. Estrella, T. Chen, M. Lloyd, J. Wojtkowiak, H. H. Cornnell, A. Ibrahim-Hashim, K. Bailey, Y. Balagurunathan, J. M. Rothberg, B. F. Sloane, J. Johnson, R. A. Gatenby and R. J. Gillies, *Cancer research*, 2013, **73**, 1524-1535.
6. A. I. Hashim, X. Zhang, J. W. Wojtkowiak, G. V. Martinez and R. J. Gillies, *NMR Biomed*, 2011, **24**, 582-591.
7. I. F. Robey, B. K. Baggett, N. D. Kirkpatrick, D. J. Roe, J. Dosecu, B. F. Sloane, A. I. Hashim, D. L. Morse, N. Raghunand, R. A. Gatenby and R. J. Gillies, *Cancer Res*, 2009, **69**, 2260-2268.
8. S. K. Parks, J. Chiche and J. Pouyssegur, *Nat Rev Cancer*, 2013, **13**, 611-623.
9. D. Neri and C. T. Supuran, *Nature reviews. Drug discovery*, 2011, **10**, 767-777.
10. X. Zhang, Y. Lin and R. J. Gillies, *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*, 2010, **51**, 1167-1170.
11. R. J. Gillies, N. Raghunand, M. L. Garcia-Martin and R. A. Gatenby, *IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society*, 2004, **23**, 57-64.
12. A. D. Sherry and M. Woods, *Annual review of biomedical engineering*, 2008, **10**, 391-411.
13. S. Aime, A. Barge, D. Delli Castelli, F. Fedeli, A. Mortillaro, F. U. Nielsen and E. Terreno, *Magn Reson Med*, 2002, **47**, 639-648.
14. S. Zhang, M. Merritt, D. E. Woessner, R. E. Lenkinski and A. D. Sherry, *Acc Chem Res*, 2003, **36**, 783-790.
15. R. J. Gillies, Z. Liu and Z. Bhujwalla, *Am J Physiol*, 1994, **267**, C195-203.
16. Z. M. Bhujwalla, C. L. McCoy, J. D. Glickson, R. J. Gillies and M. Stubbs, *Br J Cancer*, 1998, **78**, 606-611.
17. N. Raghunand, M. I. Altbach, R. van Sluis, B. Baggett, C. W. Taylor, Z. M. Bhujwalla and R. J. Gillies, *Biochemical pharmacology*, 1999, **57**, 309-312.
18. R. van Sluis, Z. M. Bhujwalla, N. Raghunand, P. Ballesteros, J. Alvarez, S. Cerdan, J. P. Galons and R. J. Gillies, *Magn Reson Med*, 1999, **41**, 743-750.
19. M. L. Garcia-Martin, G. Herigault, C. Remy, R. Farion, P. Ballesteros, J. A. Coles, S. Cerdan and A. Ziegler, *Cancer Res*, 2001, **61**, 6524-6531.
20. P. Provent, M. Benito, B. Hiba, R. Farion, P. Lopez-Larrubia, P. Ballesteros, C. Remy, C. Segebarth, S. Cerdan, J. A. Coles and M. L. Garcia-Martin, *Cancer Res*, 2007, **67**, 7638-7645.
21. S. Hunjan, R. P. Mason, V. D. Mehta, P. V. Kulkarni, S. Aravind, V. Arora and P. P. Antich, *Magnet Reson Med*, 1998, **39**, 551-556.
22. A. S. E. Ojugo, P. M. J. McSheehy, D. J. O. McIntyre, C. McCoy, M. Stubbs, M. O. Leach, I. R. Judson and J. R. Griffiths, *NMR Biomed*, 1999, **12**, 495-504.
23. J. H. Ardenkjaer-Larsen, B. Fridlund, A. Gram, G. Hansson, L. Hansson, M. H. Lerche, R. Servin, M. Thaning and K. Golman, *Proc Natl Acad Sci U S A*, 2003, **100**, 10158-10163.
24. K. R. Keshari and D. M. Wilson, *Chem Soc Rev*, 2014, **43**, 1627-1659.
25. S. J. Nelson, J. Kurhanewicz, D. B. Vigneron, P. E. Larson, A. L. Harzstark, M. Ferrone, M. van Criekinge, J. W. Chang, R. Bok, I. Park, G. Reed, L. Carvajal, E. J. Small, P. Munster, V. K. Weinberg, J. H. Ardenkjaer-Larsen, A. P. Chen, R. E. Hurd, L. I. Odegardstuen, F. J. Robb, J. Tropp and J. A. Murray, *Sci Transl Med*, 2013, **5**, 198ra108.
26. F. A. Gallagher, M. I. Kettunen, S. E. Day, D. E. Hu, J. H. Ardenkjaer-Larsen, R. Zandt, P. R. Jensen, M. Karlsson, K. Golman, M. H. Lerche and K. M. Brindle, *Nature*, 2008, **453**, 940-943.
27. A. Z. Lau, A. P. Chen, N. R. Ghugre, V. Ramanan, W. W. Lam, K. A. Connelly, G. A. Wright and C. H. Cunningham, *Magn Reson Med*, 2010, **64**, 1323-1331.
28. M. A. Schroeder, P. Swietach, H. J. Atherton, F. A. Gallagher, P. Lee, G. K. Radda, K. Clarke and D. J. Tyler, *Cardiovasc Res*, 2010, **86**, 82-91.
29. N. E. Good, G. D. Winget, W. Winter, T. N. Connolly, S. Izawa and R. M. Singh, *Biochemistry*, 1966, **5**, 467-477.
30. L. Grehn, U. Bondesson, T. Pehk and U. Ragnarsson, *J Chem Soc Chem Comm*, 1992, DOI: Doi 10.1039/C39920001332, 1332-1333.
31. G. D. Reed, C. von Morze, R. Bok, B. L. Koelsch, M. Van Criekinge, K. J. Smith, S. Hong, P. E. Larson, J. Kurhanewicz and D. B. Vigneron, *IEEE transactions on medical imaging*, 2014, **33**, 362-371.
32. C. von Morze, P. E. Z. Larson, S. Hu, K. Keshari, D. M. Wilson, J. H. Ardenkjaer-Larsen, A. Goga, R. Bok, J. Kurhanewicz and D. B. Vigneron, *Journal of Magnetic Resonance Imaging*, 2011, **33**, 692-697.
33. J. H. Ardenkjaer-Larsen, S. Macholl and H. Johannesson, *Appl Magn Reson*, 2008, **34**, 509-522.
34. D. M. Wilson, K. R. Keshari, P. E. Larson, A. P. Chen, S. Hu, M. Van Criekinge, R. Bok, S. J. Nelson, J. M. Macdonald, D. B. Vigneron and J. Kurhanewicz, *J Magn Reson*, 2010, **205**, 141-147.
35. M. Eigen, *Angewandte Chemie International Edition in English*, 1964, **3**, 1-19.
36. R. K. Ghosh, S. J. Kadlecck, M. Pourfathi and R. R. Rizi, *Magn Reson Med*, 2014, DOI: 10.1002/mrm.25530.
37. Y. Lee, N. M. Zacharias, D. Piwnica-Worms and P. K. Bhattacharya, *Chem Commun (Camb)*, 2014, **50**, 13030-13033.